CLDX
Price
$25.17
Change
-$2.37 (-8.61%)
Updated
Feb 3 closing price
Capitalization
1.67B
26 days until earnings call
Intraday BUY SELL Signals
ERAS
Price
$10.59
Change
+$8.14 (+332.24%)
Updated
Feb 3 closing price
Capitalization
3.28B
43 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CLDX vs ERAS

Header iconCLDX vs ERAS Comparison
Open Charts CLDX vs ERASBanner chart's image
Celldex Therapeutics
Price$25.17
Change-$2.37 (-8.61%)
Volume$818.24K
Capitalization1.67B
Erasca
Price$10.59
Change+$8.14 (+332.24%)
Volume$5.67M
Capitalization3.28B
CLDX vs ERAS Comparison Chart in %
View a ticker or compare two or three
VS
CLDX vs. ERAS commentary
Feb 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CLDX is a Hold and ERAS is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 04, 2026
Stock price -- (CLDX: $25.17 vs. ERAS: $10.59)
Brand notoriety: CLDX and ERAS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CLDX: 113% vs. ERAS: 94%
Market capitalization -- CLDX: $1.67B vs. ERAS: $3.28B
CLDX [@Biotechnology] is valued at $1.67B. ERAS’s [@Biotechnology] market capitalization is $3.28B. The market cap for tickers in the [@Biotechnology] industry ranges from $118.13B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CLDX’s FA Score shows that 0 FA rating(s) are green whileERAS’s FA Score has 0 green FA rating(s).

  • CLDX’s FA Score: 0 green, 5 red.
  • ERAS’s FA Score: 0 green, 5 red.
According to our system of comparison, ERAS is a better buy in the long-term than CLDX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CLDX’s TA Score shows that 3 TA indicator(s) are bullish while ERAS’s TA Score has 3 bullish TA indicator(s).

  • CLDX’s TA Score: 3 bullish, 4 bearish.
  • ERAS’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, CLDX is a better buy in the short-term than ERAS.

Price Growth

CLDX (@Biotechnology) experienced а -4.04% price change this week, while ERAS (@Biotechnology) price change was +0.81% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -4.22%. For the same industry, the average monthly price growth was +3.03%, and the average quarterly price growth was +35.17%.

Reported Earning Dates

CLDX is expected to report earnings on Mar 02, 2026.

ERAS is expected to report earnings on Mar 19, 2026.

Industries' Descriptions

@Biotechnology (-4.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ERAS($3.28B) has a higher market cap than CLDX($1.68B). ERAS YTD gains are higher at: 184.543 vs. CLDX (-7.327). ERAS has higher annual earnings (EBITDA): -131.32M vs. CLDX (-252.86M). CLDX has more cash in the bank: 583M vs. ERAS (288M). CLDX has less debt than ERAS: CLDX (2.62M) vs ERAS (48.3M). CLDX has higher revenues than ERAS: CLDX (2.6M) vs ERAS (0).
CLDXERASCLDX / ERAS
Capitalization1.68B3.28B51%
EBITDA-252.86M-131.32M193%
Gain YTD-7.327184.543-4%
P/E RatioN/AN/A-
Revenue2.6M0-
Total Cash583M288M202%
Total Debt2.62M48.3M5%
FUNDAMENTALS RATINGS
CLDX: Fundamental Ratings
CLDX
OUTLOOK RATING
1..100
65
VALUATION
overvalued / fair valued / undervalued
1..100
68
Overvalued
PROFIT vs RISK RATING
1..100
83
SMR RATING
1..100
96
PRICE GROWTH RATING
1..100
59
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
CLDXERAS
RSI
ODDS (%)
N/A
Bearish Trend 1 day ago
89%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 1 day ago
89%
Momentum
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
82%
MACD
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
87%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
82%
Bullish Trend 1 day ago
83%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
80%
Bullish Trend 1 day ago
82%
Advances
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 3 days ago
81%
Declines
ODDS (%)
Bearish Trend 6 days ago
78%
Bearish Trend 10 days ago
86%
BollingerBands
ODDS (%)
N/A
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
N/A
Bullish Trend 1 day ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
CLDX
Daily Signal:
Gain/Loss:
ERAS
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
AOFCX18.670.05
+0.27%
Alger Small Cap Focus C
EQPGX26.97N/A
N/A
Fidelity Advisor Equity Growth I
FSBCX21.79-0.01
-0.05%
Federated Hermes Global Allocation C
PGSGX18.55-0.07
-0.38%
JPMorgan Small Cap Growth A
USLUX21.54-0.19
-0.87%
US Global Investors Global Luxury Goods

CLDX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CLDX has been loosely correlated with KURA. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if CLDX jumps, then KURA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CLDX
1D Price
Change %
CLDX100%
+2.07%
KURA - CLDX
56%
Loosely correlated
-0.48%
XNCR - CLDX
55%
Loosely correlated
-0.99%
BEAM - CLDX
53%
Loosely correlated
-0.11%
IMVT - CLDX
52%
Loosely correlated
-1.07%
CRNX - CLDX
51%
Loosely correlated
+1.24%
More

ERAS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ERAS has been loosely correlated with RVMD. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if ERAS jumps, then RVMD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ERAS
1D Price
Change %
ERAS100%
-0.24%
RVMD - ERAS
57%
Loosely correlated
-1.22%
IRON - ERAS
50%
Loosely correlated
-1.17%
IDYA - ERAS
48%
Loosely correlated
+0.50%
ACLX - ERAS
48%
Loosely correlated
-0.01%
NRIX - ERAS
48%
Loosely correlated
-1.76%
More